Corbus Pharmaceuticals
CRBP
54 hedge funds and large institutions have $116M invested in Corbus Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 8 closing their positions.
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
10% more funds holding
Funds holding: 49 → 54 (+5)
5% more capital invested
Capital invested by funds: $110M → $116M (+$5.59M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.02% less ownership
Funds ownership: 0.98% → 0.96% (-0.02%)
23% less call options, than puts
Call options by funds: $7.59M | Put options by funds: $9.83M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$9.61M |
| 2 |
BlackRock
New York
|
+$5.44M |
| 3 |
IA
IFP Advisors
Tampa,
Florida
|
+$3.89M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.34M |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.66M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$1.36M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.29M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$1.06M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$854K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $4K | +$4.17K | +17 | New |
|
|
SPIA
52
Steward Partners Investment Advisory
New York
| $2K | +$2.45K | +10 | New |
|
|
TC
53
Trust Company
Manhattan,
Kansas
| $1K | +$736 | +3 | New |
|
|
54
Russell Investments Group
London,
United Kingdom
| – | -$854K | -3,312 | Closed |
|
55
Jane Street
New York
| – | -$572K | -2,255 | Closed |
|
|
SSA
56
Schonfeld Strategic Advisors
New York
| – | -$234K | -925 | Closed |
|
|
BII
57
Bainco International Investors
Boston,
Massachusetts
| – | -$169K | -667 | Closed |
|
58
Simplex Trading
Chicago,
Illinois
| – | -$67K | -273 | Closed |
|
|
AIM
59
Acrospire Investment Management
Chicago,
Illinois
| – | -$36K | -144 | Closed |
|
|
SIG
60
Stanford Investment Group
Mountain View,
California
| – | -$31K | -122 | Closed |
|
|
TRCT
61
Tower Research Capital (TRC)
New York
| – | -$4K | -17 | Closed |
|
|
IIC
62
Integrated Investment Consultants
Bloomfield Hills,
Michigan
| – | +$491 | +2 | New |
|
CRBP Hedge Fund Activity: Q1 2017 in Review
54 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2017, worth a combined $116M — up 5.1% from $110M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CRBP positions and 8 closed out — a net gain of 10 holders — while 21 added to existing stakes and 10 trimmed.
The largest buyer was Knoll Capital Management, adding an estimated $9.61M. The largest seller was Cormorant Asset Management, cutting an estimated $6.66M.
- 54 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2017, up from 49 in Q4 2016.
- Funds reported $116M of Corbus Pharmaceuticals stock for Q1 2017, up 5.1% quarter-over-quarter.
- 18 funds opened new Corbus Pharmaceuticals positions in Q1 2017 and 8 closed out, a net change of +10 holders.
- The largest Corbus Pharmaceuticals buyer in Q1 2017 was Knoll Capital Management, an estimated $9.61M added.
- The largest Corbus Pharmaceuticals seller in Q1 2017 was Cormorant Asset Management, an estimated $6.66M sold.
Based on aggregated 13F filings for Q1 2017.